412-246-6111

 

Mifepristone vs. Placebo for Treatment of Patients with Major Depression with Psychotic Features

(CORCEPT)

 

 

Home     Depression     Bipolar Disorder     Cognitive Therapy     Research     Staff     Contact    TV ADs

 

 

Current Studies

Depression:

* Buprenorphine for TRD

* Mifepristone for Psychotic Depression (CORCEPT)

Assessment Only:

* Emotion/Physiology

 
Purpose

Approximately 450 patients will be randomized to receive CORLUX® (Mifepristone) or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of CORLUX followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.


Condition Intervention Phase
Psychotic Depression
Major Depression With Psychotic Features
Psychosis
 
Drug: mifepristone
Drug: placebo
 
Phase 3
 

 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CORLUX (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

 

Eligibility

Ages Eligible for Study:   22 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

 

 

For further information please call 412-246-6111, click here to email us, or visit clinicaltrials.gov.

 

 
 

If you have any questions or comments about this web site, please contact the webmaster.  For all other questions please click the contact link.

This website was last updated 08/16/2013.

© 2005 Mood Disorders Treatment and Research Program (MDTRP), Department of Psychiatry, Western Psychiatric Institute and Clinic (WPIC), UPMC Health System